Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | POLB | P06746 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21993211 | 0.86 | MEN1 (0.63) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11090836 | 0.83 | RAB9A (0.78) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11090834 | 0.83 | RAB9A (0.78) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11080699 | 0.82 | RAB9A (0.78) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11080702 | 0.82 | RAB9A (0.78) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11112931 | 0.80 | ALOX5 (0.65) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11112929 | 0.80 | ALOX5 (0.65) | MEN1KMT2APOLBALDH1A1THRB | |
| SCHEMBL11082846 | 0.80 | MEN1 (0.78) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL11082848 | 0.80 | MEN1 (0.78) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL28045595 | 0.79 | MEN1 (0.66) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200147088-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147088-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS1, LGALS2, LGALS3 | MEN1 523/4885KMT2A 4754/4885POLB 4727/4885 |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | MEN1 523/4885KMT2A 4754/4885POLB 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.